For example, ERRFI1 downregulation by MRTX1133 (a KRASG12D inhibitor) leads to EGFR activation and subsequent MRTX1133 resistance in KRASG12D-mutant CRC cells [8]. Here, EGFR is linked to colorectal carcinoma.